Catalio Capital Management (Catalio), a multi-strategy life sciences investment firm, has closed its third venture fund, Catalio Nexus Fund III (Fund III), with more than $381 million in total capital commitments, exceeding its original $300 million dollar target.
Catalio Capital Management (Catalio), a multi-strategy life sciences investment firm, has closed its third venture fund, Catalio Nexus Fund III (Fund III), with more than $381 million in total capital commitments, exceeding its original $300 million dollar target.
The fund received significant backing from current Catalio investors and a number of new, global institutional investors, foundations and endowments.
Launched in 2020 and led by Co-Founders George Petrocheilos and Dr Jacob Vogelstein, Catalio manages more than $1 billion in assets across its private equity, private credit, and public equities strategies. Fund III is Catalio’s largest closed-end fund to date. Previously, Catalio raised $15 million for Nexus Fund I and $100 million for Nexus Fund II.
Consistent with the successful approach of its predecessor vehicles, Fund III will invest in breakthrough biomedical technology companies at all stages of growth, from inception to IPO. Many of the companies in which the fund invests are founded by Catalio Venture Partners, a group of 36 serial scientist-entrepreneurs at top-tier academic institutions in the US and Europe, each with a successful track record of starting up and spinning out businesses.
